$23.40
Value $196M
ELMD and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$23.40
Value $196M
$272.70
Value $657B
Electromed (ELMD) has a market value of $196M and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, ELMD moved -5.0% and JNJ +39.7%. The P/E is 16.4 for ELMD and 40.8 for JNJ. Dividend yield: ELMD none, JNJ 1.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ELMD$196M
JNJ$657B
JNJ is 3,357 times ELMD
Revenue, 12 months
ELMD$76M
JNJ$99.3B
JNJ is 1,314 times ELMD
Net income, 12 months
ELMD$12M
JNJ$16.1B
JNJ is 1,350 times ELMD
Operating margin
ELMD19.5%
JNJ–
ROIC
ELMD23.5%
JNJ12.4%
11.1 points apart
P/E
ELMD16.4
JNJ40.8
JNJ is 2.5 times ELMD
Dividend yield
ELMD0.0%
JNJ1.9%
1.9 points apart
5-year return
ELMD+98.0%
JNJ+92.0%
6.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ELMD+98.0%
JNJ+92.0%
| Period | ELMDWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -5.0%Price -5.0% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | +122.9%+30.6% a yearPrice +122.9% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | +98.0%+14.6% a yearPrice +98.0% | +92.0%+13.9% a yearPrice +67.0% |
| 10 years since November 18, 2016 | +418.8%+17.9% a yearPrice +418.8% | +208.0%+11.9% a yearPrice +136.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ELMDElectromedJNJJohnson & Johnson
| Price | $23.40 | $272.70 |
|---|---|---|
| Market value | $196M | $657B |
| Enterprise value (EV) | $180M | $685B |
| P/E | 16.4 | 40.8 |
| P/E, 5-year median | 29.8 | 21.9 |
| P/B | 3.7 | 8.1 |
| EV/EBIT | 12.2 | 38.6 |
| Free cash flow yield | 4.5% | 3.1% |
| Revenue, 12 months | $76M | $99.3B |
|---|---|---|
| Net income, 12 months | $12M | $16.1B |
| Free cash flow, 12 months | $8.7M | $20.6B |
| Earnings per share, 12 months | $1.38 | $6.59 |
| Revenue growth, year on year | 15.3% | 6.1% |
| Revenue growth a year, past | +15.6%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | +36.9%over 5 years | +14.9%over 5 years |
| Gross margin | 79.0% | 67.6% |
|---|---|---|
| Operating margin | 19.5% | – |
| Net margin | 15.8% | 16.2% |
| ROIC | 23.5% | 12.4% |
| ROE | 24.3% | 19.7% |
| Cash | $16M | $17.2B |
|---|---|---|
| Total debt | $133.0K | $44.7B |
| Net debt / EBITDA | -1.0 | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 2.0% | 0.9% |
| Shareholder yield | 2.0% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 3,356.9 times Electromed ($196M), at today's prices.
Since November 18, 2016, ELMD's price moved +418.8% and JNJ's +136.4%. With dividends: ELMD +418.8% (+17.9% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Electromed and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 16.4 for ELMD and 40.8 for JNJ. The median of the last five years was 29.8 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.8% for Electromed and 16.2% for Johnson & Johnson, and the operating margin 19.5% and –. Revenue was $76M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.